Assessment of potential drug interactions in patients with epilepsy: Impact of age and sex

Neurology

Volumn 72, Issue 5, 2009, Pages 419-425

  Gidal, Barry E ^a   French, Jacqueline A ^b   Grossman, Patricia ^c   Le Teuff, Gwénaël ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Atlanta Cardiovascular Res Inst   (United States)

^d Keyrus Biopharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CONTRACEPTIVE AGENT; CYCLOPHOSPHAMIDE; ETIRACETAM; ETOPOSIDE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; LAMOTRIGINE; METHOTREXATE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SEROTONIN UPTAKE INHIBITOR; TENIPOSIDE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ZONISAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; EPILEPSY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES; ADOLESCENT; AGE; AGING; DRUG EFFECT; DRUG INTERACTION; ENZYME ACTIVATION; MIDDLE AGED; PHYSIOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; ENZYME ACTIVATION; EPILEPSY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLYPHARMACY; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; YOUNG ADULT;

EID: 61549107236     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000341789.77291.8d     Document Type: Article

References (40)

1. Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35 (suppl 2):S1-S6.
2. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71:576-586.
3. Brodie M, Kwan P. Epilepsy in elderly people. BMJ 2005; 331:1317-1322.
4. Cloyd J, Hauser W, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 2006;68 (suppl 1):S39-S48.
5. Collins NS, Shapiro RA, Ramsay RE. Elders with epilepsy. Med Clin North Am 2006;90:945-966.
6. Ramsay RE, Macias FM, Rowan AJ. Diagnosing epilepsy in the elderly. Int Rev Neurobiol 2007;81:129-151.
7. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5:3-14.
8. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit 2007;13:RA1-RA7.
9. Ochoa JG, Riche W. Antiepileptic drugs: an overview. Available at: http://www.emedicine.com/neuro/. Accessed April 2, 2007.
10. Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006;66:1817-1829.
11. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-385.
12. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-356.
13. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-255.
14. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205.
15. French JA, Gidal BE. Antiepileptic drug interactions. Epilepsia 2000;41 (suppl 8):S30-S36.
16. Gareri P, Gravina T, Ferreri G, De Sarro G. Treatment of epilepsy in the elderly. Prog Neurobiol 1999;58:389-407.
17. Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res 2006;68 (suppl 1):S49-S63.
18. Tatro DS. Drug Interaction Facts. St. Louis, MO: Facts & Comparisons; 2007.
19. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA 2002;287:337-344.
20. Pugh MJ, Cramer J, Knoefel J, et al. Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc 2004;52:417-422.
21. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-563.
22. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;23 (suppl 4):3-8.
23. Xu C, Li CY, Kong AN. Induction of phase I, II, III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-269.
24. Arnett DK, Jacobs DR Jr, Luepker RV, Blackburn H, Armstrong C, Claas SA. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 2005;112:3884-3891.
25. Gaitatzis A, Carroll K, Majeed AW, Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004;45:1613-1622.
26. Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997;38:1062-1068.
27. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999-2000: a rising tide. Hypertension 2004;44: 398-404.
28. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1991;32:335-340.
29. Bramswig S, Kerksiek A, Sudhop T, Luers C, Von Bergmann K, Berthold HK. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol 2002;282:H704-H716.
30. Demircioglu S, Soylu A, Dirik E. Carbamazepine and valproic acid: effects on serum lipids and liver functions in children. Pediatr Neurol 2000;23:142-146.
31. Attilakos A, Papakonstantinou E, Schulpis K, et al. Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res 2006;71:229-232.
32. James GK, Jones MW, Pudek MR. Homocysteine levels in patients on phenytoin therapy. Clin Biochem 1997;30: 647-649.
33. Gidal BE, Tamura T, Hammer A, Vuong A. Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 2005;64: 161-166.
34. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004;59:879-882.
35. Patsalos P, Perucca E. Clinically important drug interactions in epilepsy: interaction between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481.
36. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43 (suppl 2):37-44.
37. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 2005;4:627-634.
38. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-409.
39. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285-290.
40. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005; 72:255-260.